Changeflow GovPing Healthcare & Life Sciences SUVEXX Assay Out of Specification Recall - Lot ...
Urgent Enforcement Amended Final

SUVEXX Assay Out of Specification Recall - Lot 0000159323

Favicon for recalls-rappels.canada.ca Health Canada Recalls & Safety Alerts
Filed
Detected
Email

Summary

Health Canada has issued a Type III recall for SUVEXX tablets (DIN 02496305, containing Sumatriptan 85mg and Naproxen sodium 500mg), lot 0000159323, distributed nationally in Canada. The recall was initiated after the assay was found to be out of specification in the affected lot. Aralez Pharmaceuticals Canada Inc. issued the recall with a depth covering retailers. Patients and healthcare providers are advised to verify if their product is affected and to consult a healthcare provider before discontinuing use.

Published by HC on recalls-rappels.canada.ca . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

Health Canada issued a Type III health product recall for SUVEXX tablets (Sumatriptan 85mg/Naproxen sodium 500mg), lot 0000159323, manufactured by Aralez Pharmaceuticals Canada Inc. The recall was triggered by an out-of-specification assay result detected during quality testing. The product was distributed nationally through retail channels.

Pharmaceutical distributors, retailers, and healthcare providers in possession of this lot should immediately verify their inventory and quarantine any affected stock. Patients who have received SUVEXX from this lot should consult their healthcare provider before making any changes to their medication regimen. The Type III classification indicates a situation where use of, or exposure to, the affected product is not likely to cause adverse health consequences, but the recall is being conducted as a precautionary measure.

What to do next

  1. Verify if your product is affected.
  2. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
  3. Contact the recalling firm if you have any questions about the recall.
  4. Report any health product related side effects to Health Canada.
  5. Report any other health product safety complaints to Health Canada.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Health product recall

SUVEXX: The assay is out of specification in the affected lot.

Brand(s)

SUVEXX

Last updated

2026-04-20

Summary

Product SUVEXX Issue Health products - Product quality What to do Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.

Distribution National

Affected products

Product Name Market Authorization Dosage Form Strength Lot number
SUVEXX DIN 02496305 Tablet Sumatriptan 85mg
Naproxen sodium 500mg 0000159323

Issue

The assay is out of specification in the affected lot.

What you should do

  1. Verify if your product is affected.
  2. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
  3. Contact the recalling firm if you have any questions about the recall.
  4. Report any health product related side effects to Health Canada.
  5. Report any other health product safety complaints to Health Canada.

Additional information

Background

Depth of recall: Retailers

Details

Original published date:

2026-04-20

Alert / recall type Health product recall Category Health products - Drugs Companies ARALEZ PHARMACEUTICALS CANADA INC

6733 Mississauga Rd, Suite 800

Mississauga, ON

L5N 6J5

Published by Health Canada Audience General public Healthcare Industry Distribution National Recall class Type III Recall date

2026-04-15

Identification number RA-81912

Get notified

Receive emails about new and updated recall and safety alerts.

Subscribe

Report a health or safety concern

Named provisions

Issue - The assay is out of specification in the affected lot What you should do

Mentioned entities

Get daily alerts for Health Canada Recalls & Safety Alerts

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from HC.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
HC
Filed
April 20th, 2026
Instrument
Enforcement
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Patients
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug recall response Quality assurance verification Product quarantine
Geographic scope
Canada CA

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Product Safety Healthcare

Get alerts for this source

We'll email you when Health Canada Recalls & Safety Alerts publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!